TY - JOUR
T1 - Exosomal microRNAs from longitudinal liquid biopsies for the prediction of response to induction chemotherapy in high-risk neuroblastoma patients
T2 - A proof of concept SIOPEN study
AU - Morini, Martina
AU - Cangelosi, Davide
AU - Segalerba, Daniela
AU - Marimpietri, Danilo
AU - Raggi, Federica
AU - Castellano, Aurora
AU - Fruci, Doriana
AU - De Mora, Jaime Font
AU - Cañete, Adela
AU - Yáñez, Yania
AU - Viprey, Virginie
AU - Corrias, Maria Valeria
AU - Carlini, Barbara
AU - Pezzolo, Annalisa
AU - Schleiermacher, Gudrun
AU - Mazzocco, Katia
AU - Ladenstein, Ruth
AU - Sementa, Angela Rita
AU - Conte, Massimo
AU - Garaventa, Alberto
AU - Burchill, Susan
AU - Luksch, Roberto
AU - Bosco, Maria Carla
AU - Eva, Alessandra
AU - Varesio, Luigi
PY - 2019/10
Y1 - 2019/10
N2 - Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.
AB - Despite intensive treatment, 50% of children with high-risk neuroblastoma (HR-NB) succumb to their disease. Progression through current trials evaluating the efficacy of new treatments for children with HR disease usually depends on an inadequate response to induction chemotherapy, assessed using imaging modalities. In this study, we sought to identify circulating biomarkers that might be detected in a simple blood sample to predict patient response to induction chemotherapy. Since exosomes released by tumor cells can drive tumor growth and chemoresistance, we tested the hypothesis that exosomal microRNA (exo-miRNAs) in blood might predict response to induction chemotherapy. The exo-miRNAs expression profile in plasma samples collected from children treated in HR-NBL-1/SIOPEN before and after induction chemotherapy was compared to identify a three exo-miRs signature that could discriminate between poor and good responders. Exo-miRNAs expression also provided a chemoresistance index predicting the good or poor prognosis of HR-NB patients.
KW - Chemotherapy response
KW - Exosomes
KW - Liquid biopsy
KW - MiRNA
KW - Neuroblastoma
UR - http://www.scopus.com/inward/record.url?scp=85073429184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073429184&partnerID=8YFLogxK
U2 - 10.3390/cancers11101476
DO - 10.3390/cancers11101476
M3 - Article
AN - SCOPUS:85073429184
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 10
M1 - 1476
ER -